Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: Economic evaluation of a cluster randomized controlled trial study

Arthritis Care and Research

Volumn 66, Issue 6, 2014, Pages 810-816

  Marra, Carlo A ^a,b   Grubisic, Maja ^a   Cibere, Jolanda ^a,b   Grindrod, Kelly A ^c   Woolcott, John C ^a,d   Gastonguay, Louise ^a   Esdaile, John M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DOCTOR PATIENT RELATION; EXERCISE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MONEY; PATIENT CARE; PATIENT EDUCATION; PHARMACIST; PHYSIOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

COMBINED MODALITY THERAPY; COSTS AND COST ANALYSIS; EXERCISE THERAPY; HUMANS; OSTEOARTHRITIS, KNEE; PAIN MANAGEMENT; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PROFESSIONAL ROLE; TREATMENT OUTCOME;

EID: 84901660151     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22232     Document Type: Article

References (18)

1. Glazier RH, Badley EM, Wright JG, Coyte PC, Williams JI, Harvey B, et al. Patient and provider factors related to comprehensive arthritis care in a community setting in Ontario, Canada. J Rheumatol 2003; 30: 1846-50.
2. Grindrod KA, Marra CA, Colley L, Cibere J, Tsuyuki RT, Esdaile JM, et al. After patients are diagnosed with knee osteoarthritis, what do they do? Arthritis Care Res (Hoboken) 2010; 62: 510-5.
3. Ganz DA, Chang JT, Roth CP, Guan M, Kamberg CJ, Niu F, et al. Quality of osteoarthritis care for community-dwelling older adults. Arthritis Rheum 2006; 55: 241-7.
4. Marra CA, Cibere J, Grubisic M, Grindrod KA, Gastonguay L, Thomas JM, et al. Pharmacist-initiated intervention trial in osteoarthritis: a multidisciplinary intervention for knee osteoarthritis. Arthritis Care Res (Hoboken) 2012; 64: 1837-45.
5. Marra CA, Cibere J, Tsuyuki RT, Soon JA, Esdaile JM, Gastonguay L, et al. Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis Rheum 2007; 57: 1238-44.
6. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH,. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004; 51: 193-202.
7. Pouchot J, Kopec JA, Latteier J, Sayre EC, Al-Harthy F, Garbuz D, et al. Validity of a new adaptive measure of health-related quality of life in arthritis [abstract]. Qual Life Res 2004; 13: 1590.
8. Blanchard C, Feeny D, Mahon JL, Bourne R, Rorabeck C, Stitt L, et al. Is the Health Utilities Index responsive in total hip arthroplasty patients? J Clin Epidemiol 2003; 56: 1046-54.
9. Canadian Pharmacists Association. Summary of pharmacists' expanded scope of practice activities across Canada. 2013. URL: http://blueprintforpharmacy.ca/ docs/kt-tools/pharmacists'-expanded-scope-summary-chart-cpha-october-2013.pdf.
10. Medical Services Plan, Medical Services Commission. Payment schedule. British Columbia: Ministry of Health, Government of British Columbia; 2009.
11. Liljas B,. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13: 1-7.
12. Drummond MF, O'Brien B, Stoddart GL, Torrance GW,. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997.
13. Briggs A, Clark T, Wolstenholme J, Clarke P,. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003; 12: 377-92.
14. Oostenbrink JB, Al MJ,. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-76.
15. Oostenbrink JB, Al MJ, Rutten-van Molken MP,. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics 2003; 21: 1103-12.
16. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force. Value Health 2005; 8: 521-33.
17. Yuan YC,. Multiple imputation for missing data: concepts and new development. Version 9.0. 1999. URL: http://www.ats.ucla.edu/stat/sas/library/ multipleimputation.pdf.
18. Briggs A, Fenn P,. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723-40.